0001102624-16-003316.txt : 20160825 0001102624-16-003316.hdr.sgml : 20160825 20160825163151 ACCESSION NUMBER: 0001102624-16-003316 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20160825 DATE AS OF CHANGE: 20160825 EFFECTIVENESS DATE: 20160825 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Boston Therapeutics, Inc. CENTRAL INDEX KEY: 0001473579 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 270801073 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-269587 FILM NUMBER: 161851950 BUSINESS ADDRESS: STREET 1: 33 SOUTH COMMERCIAL STREET CITY: MANCHESTER STATE: NH ZIP: 03101 BUSINESS PHONE: 978-886-0421 MAIL ADDRESS: STREET 1: 33 SOUTH COMMERCIAL STREET CITY: MANCHESTER STATE: NH ZIP: 03101 FORMER COMPANY: FORMER CONFORMED NAME: AVANYX Therapeutics, Inc. DATE OF NAME CHANGE: 20091001 D 1 primary_doc.xml X0707 D LIVE 0001473579 Boston Therapeutics, Inc. 1750 Elm Street MANCHESTER NH NEW HAMPSHIRE 03104 603-935-9799 DELAWARE AVANYX Therapeutics, Inc. Corporation true Carl W. Rausch 1750 Elm Street Manchester NH NEW HAMPSHIRE 03104 Executive Officer CEO Dale Conway 1750 Elm Street Manchester NH NEW HAMPSHIRE 03104 Director Chairman Rom Eliaz 1750 Elm Street Manchester NH NEW HAMPSHIRE 03104 Director Henry Esber 1750 Elm Street Manchester NH NEW HAMPSHIRE 03104 Director Colin Neill 1750 Elm Street Manchester NH NEW HAMPSHIRE 03104 Director Pharmaceuticals Decline to Disclose 06b false 2016-08-12 false true true true true Convertible Promissory Notes and Warrants false 25000 Maxim Group, LLC 120708 None None 405 Lexington Avenue New York NY NEW YORK 10174 AL ALABAMA AR ARKANSAS CA CALIFORNIA FL FLORIDA IL ILLINOIS IA IOWA LA LOUISIANA MO MISSOURI NJ NEW JERSEY NM NEW MEXICO NY NEW YORK PA PENNSYLVANIA TX TEXAS VA VIRGINIA false 2000000 1322500 677500 false 25 132250 0 Placement agent will receive a 10% commission and a warrant to purchase a number of shares equal to 10% of the aggregate number of shares sold. 100000 true Working capital. false Boston Therapeutics, Inc. /s/Carl W. Rausch Carl W. Rausch Chief Executive Officer 2016-08-24